** Healthcare conglomerate CVS Health CVS.N on Thursday raised its full-year profit forecast and disclosed plans to exit Obamacare market in 2026
** Under the leadership of CEO David Joyne, CVS is navigating one of the most challenging periods in its six-decade history
** Median PT of 29 brokerages covering the stock is $74, according to data compiled by LSEG
POSITIVE SIGNS
** Leerink Partners ("outperform" PT: $83) says CVS is set for "slow and steady win" for its earnings and first-quarter results don't impact its ongoing "power recovery" or 2026 results
** J.P.Morgan ("overweight") says CVS is taking a "prudent stance" for the full year, but there seems to be early positive signs such as "slightly better than expected" demand trends in Medicare Advantage plans
** Says CVS' partnership with Novo Nordisk NOVOb.CO is not reflected in the company's annual forecast and will be a "notable area to watch"
** Oppenheimer ("perform") says while the move to exit Obamacare business was a "little surprising," CVS management said it did not see a near- or long-term way to improve its position in that market
** Mizuho (outperform, PT: $76) says that a key issue for investors is CVS' exposure to increased tariffs via its retail pharmacy segment
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.